A finely-tuned understanding of cancer biomolecular alterations led to major improvements for patient management as illustrated by the targeting of EGFR (epidermal growth factor receptor) alterations or ALK (anaplastic lymphoma kinase)/ROS1 (ROS proto-oncogene 1) rearrangements in NSCLC [115]. This evidence concerns the gene ALK and non-small cell lung carcinoma.